BSE · 530313
Kimia Biosciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹120 Cr with net profit ₹10 Cr — a 7.99% net margin, versus -4.98% the period before.
Shareholding
As of 2026-06-30
- Promoter74.94%
- Public24.68%
- DII0.38%
12,775 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.7× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — SDD. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #15 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,07,995 Cr | 276.76 | 12.39 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,475 Cr | 200.98 | 16.01 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,636 Cr | 68.22 | 13.15 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,317 Cr | 127.37 | 2.14 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,768 Cr | 68.23 | 2.43 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,509 Cr | 34.4 | 4.47 | 12.98% | 11.5% |
| Hikal Limited | ₹2,676 Cr | 185.46 | 2.24 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,234 Cr | 246.74 | 9.13 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,026 Cr | 42.12 | 6.16 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,370 Cr | 69.88 | 3.29 | 17.67% | 13.66% |
| Kimia Biosciences Limited(this company) | ₹147 Cr | 19.75 | 8.28 | 41.95% | 6.47% |
AI analysis
AI-generated · google/gemini-2.5-flashKimia Biosciences Limited is listed on the Indian markets. The company reported a market capitalization of Rs 161 Cr. The Price-to-Earnings ratio is 21.65, with an EPS of 1.57. The Return on Equity (ROE) stands at 41.95%, and the Return on Capital Employed (ROCE) is 22.8087%. The debt-to-equity ratio is 7.46, and the profit margin is 6.47%.
Positives
- +The Return on Equity (ROE) is 41.95%.
- +The Return on Capital Employed (ROCE) is 22.8087%.
- +Net profit recorded a significant turnaround from a loss of Rs -5.3087 Cr in Mar 2024 to a profit of Rs 9.6124 Cr in Mar 2025.
- +Promoter holding is high at 74.9392% as of Mar 2026.
- +No promoter shares are reported as pledged.
Negatives
- −The company's debt-to-equity ratio is high at 7.46.
- −The company is currently under a surveillance measure (SDD).
- −Annual revenue decreased by 17.81% from Rs 129.7291 Cr in Mar 2023 to Rs 106.5183 Cr in Mar 2024.
Financial Performance
Kimia Biosciences Limited experienced variability in its annual revenue. Revenue decreased by 17.81% from Rs 129.7291 Cr in Mar 2023 to Rs 106.5183 Cr in Mar 2024. However, revenue subsequently increased by 12.87% to Rs 120.2411 Cr in Mar 2025. Annual net profit showed a significant recovery, moving from a loss of Rs -5.3087 Cr in Mar 2024 to a profit of Rs 9.6124 Cr in Mar 2025. The company's EPS also recovered, from -1.12 in Mar 2024 to 2.03 in Mar 2025.
Profitability & Returns
The company's profitability has shown improvement. The Reported Return on Equity (ROE) is 41.95%, and the Return on Capital Employed (ROCE) is 22.8087%. The profit margin for the latest available period is 6.47%. While annual net profit had been negative for several years, it turned positive at Rs 9.6124 Cr in Mar 2025, from a loss of Rs -5.3087 Cr in Mar 2024.
Balance Sheet
The company carries a high level of debt relative to equity, with a debt-to-equity ratio of 7.46. The book value per share is Rs 3.75. Further details regarding assets, liabilities, and specific debt components are not available in the provided data.
Ownership & Pledges
There are no FII holdings reported. The historical data indicates a general stability in the number of shareholders, with 12,775 shareholders reported as of Mar 2026. No promoter shares are reported as pledged.
Regulatory & Surveillance
Kimia Biosciences Limited is currently under a surveillance measure identified as SDD, according to the provided data. This implies increased scrutiny from regulatory bodies regarding its trading activity. Further details on the specific reasons or implications of the SDD measure are not available.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.